Burlington, Ontario Apr 7, 2022 (Issuewire.com) - Leader Research announces the commencement of participant recruiting for a cold urticaria clinical trial in Ontario, Canada. The trial will assist Canadian researchers in learning ways to improve the quality of life for those suffering from chronic inducible cold urticaria (“ColdU”).
The Health Canada-approved study (protocol code number EFC16720) is being conducted by Canadian dermatologists to determine if the medication can reduce the itchy wheals and angioedema commonly associated with cold urticaria and also improve patients' quality of life. Cold urticaria is often managed with antihistamine treatment, which is not universally effective.
The research team invites Ontario residents who are afflicted with cold urticaria to apply for participation in the study. Applicants may be eligible if they are between 18 and 80 years old and have the presence of itchy wheals and/or angioedema due to cold despite the use of H1 antihistamine treatment.
Participants will receive study-related medical care at no cost and will be seen by a doctor who will monitor their cold urticaria condition for the duration of the study. Their participation may contribute to the development of new treatment options, and they may also receive reimbursement for study-related expenses of up to $75.00 for each clinical visit.
Ontario residents who are potentially eligible for this important research are asked to visit leaderresearch.ca or to call 289-812-0046 to learn more.
About cold urticaria
Cold urticaria (“ColdU”) is an adverse skin reaction that appears after exposure to cold air, liquid, or surfaces. Afflicted people may develop itchy wheals (hives) soon after exposure, sometimes worsening as the skin warms. Reactions can be severe, including anaphylaxis resulting in low blood pressure and difficulty breathing. There is currently no approved treatment available for Chronic Inducible ColdU.
Media Contact
Leader Research *****@leaderresearch.ca http://leaderresearch.ca
